Relmada Therapeutics today announced that $3 million in Series A proceeds from stakeholders and investors will be used to continue the development of the opioid LevoCap.
Providing a once-daily extended release dosage of levorphanol, LevoCap is intended to treat chronic pain and potentially reverse a patient's analgesic tolerance to morphine.
Relmada anticipates launching a Phase 3 study for the drug in 2013, according to CEO Sergio Traversa.
Dr. Daniel Carr Named PAINWeek 2012 Keynote Speaker
Neurostimulation Field Draw Investor Attention
Providing a once-daily extended release dosage of levorphanol, LevoCap is intended to treat chronic pain and potentially reverse a patient's analgesic tolerance to morphine.
Relmada anticipates launching a Phase 3 study for the drug in 2013, according to CEO Sergio Traversa.
Related Articles on Pain Management:
Middle Fork Surgery Center Visited by Oregon's Co-Speaker of the HouseDr. Daniel Carr Named PAINWeek 2012 Keynote Speaker
Neurostimulation Field Draw Investor Attention